Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample.
What is Biocept's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BIOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BIOC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIOC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIOC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIOC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Biocept's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
MikeNall(56yo)
6.3yrs
Tenure
US$439,720
Compensation
Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales, ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD439.72K) is about average for companies of similar size in the US market ($USD508.62K).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.4yrs
Average Tenure
61yo
Average Age
Experienced Management: BIOC's management team is considered experienced (3.4 years average tenure).
Board Age and Tenure
8.7yrs
Average Tenure
71yo
Average Age
Experienced Board: BIOC's board of directors are considered experienced (8.7 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 615.8%.
Management Team
Soon Kap Hahn
Tenure: 22.9yrs
Mike Terry (64yo)
Senior Vice President of Corporate Development
Tenure: 0yrs
Lyle Arnold (72yo)
Senior VP of R&D
Tenure: 0yrs
Compensation: US$287.43k
David Moskowitz
Vice President of Strategy & Corporate Communications
Tenure: 3.2yrs
Michael Brown
General Counsel and Compliance & Privacy Officer
Tenure: 2.2yrs
Tim Kennedy (61yo)
CFO, Senior VP of Operations & Corporate Secretary
Tenure: 3.4yrs
Compensation: US$359.04k
Pavel Tsinberg
Director of Technology Development
Tenure: 2.3yrs
Mike Nall (56yo)
CEO, President & Director
Tenure: 6.3yrs
Compensation: US$439.72k
Veena Singh (44yo)
Senior Medical Director
Tenure: 5yrs
Compensation: US$115.22k
Cory Dunn
Vice President of Marketing
Tenure: 1.1yrs
Board Members
M. Wilson (81yo)
Lead Independent Director
Tenure: 0yrs
Compensation: US$56.16k
Ivor Royston (73yo)
Independent Director
Tenure: 9.9yrs
Compensation: US$41.16k
David Hale (70yo)
Non-Executive Chairman of the Board
Tenure: 8.8yrs
Compensation: US$102.41k
Bruce Huebner (68yo)
Independent Director
Tenure: 6.1yrs
Compensation: US$47.66k
Lyle Arnold (72yo)
Senior VP of R&D
Tenure: 0yrs
Compensation: US$287.43k
Claire Reiss
Chairwoman Emeritus
Tenure: 8.7yrs
Marsha Chandler (74yo)
Independent Director
Tenure: 6.1yrs
Compensation: US$39.91k
Fred Hirsch
Member of Clinical Advisory Board
Tenure: 0yrs
Bruce Gerhardt (68yo)
Independent Director
Tenure: 9.2yrs
Compensation: US$38.66k
Mike Nall (56yo)
CEO, President & Director
Tenure: 6.3yrs
Compensation: US$439.72k
Company Information
Biocept, Inc.'s company bio, employee growth, exchange listings and data sources
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/05 00:43
End of Day Share Price
2019/12/04 00:00
Earnings
2019/09/30
Annual Earnings
2018/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.